Article

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell therapy

2022-05-17

Abstract excerpt

<h4>Summary</h4> Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a compelling tumor-associated cell surface antigen for therapeutic targeting in solid tumors. We identified broad expression of STEAP1 (87% positive) in lethal metastatic prostate cancer, even more so than prostate-specific membrane antigen (PSMA, 60% positive) which is a clinically established diagnostic and therapeutic target. S...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 96ee2226-233e-5299-912b-325005e86a7c
DOI: 10.1101/2022.05.16.492156

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell therapyDOI 10.1101/2022.05.16.492156Read

Exploring STEAP1 Expression in Prostate Cancer Cells in Response to Androgen Deprivation and in Small Extracellular VesiclesSemantic proximity Read

Development of a STEAP1-Targeted Prostate Cancer Specific Antibody Drug Conjugate Platform with Immunostimulatory PropertiesSemantic proximity Read

The role of STEAP2 in aggressive prostate cancer traits and androgen responsesSemantic proximity Read

Six-transmembrane epithelial antigen of the prostate (STEAP1 and STEAP2)-differentially expressed by murine and human mesenchymal stem cells.Semantic proximity Read

Single Cell Analysis of Treatment–Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted TherapiesSemantic proximity Read

A multifunctional T-cell engager containing CD80 enhances prostate cancer treatmentSemantic proximity Read

Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen–targeted therapiesSemantic proximity Read

<i>Collagen-binding IL-12 expressing</i> STEAP1 CAR-T cells reduce toxicity and eradicate mouse prostate cancer in combination with checkpoint inhibitorsSemantic proximity Read

Armoring STEAP1 CAR T cells with IL-18 potentiates antitumor activity in Ewing sarcomaSemantic proximity Read

Targeting Chromatin Effector Pygo2 to Enhance Immunotherapy in Prostate CancerSemantic proximity Read

Mapping Tumor Epitope Space by Direct Selection of Single-Chain Fv Antibody Libraries on Prostate Cancer CellsSemantic proximity Read

Deciphering the tumor-specific immunopeptidome <i>in vivo</i> with genetically engineered mouse modelsSemantic proximity Read